Drugs Technology (DrugsTech) was established in 2006 by leading Russian pharmaceutical experts, scientists and executives with the ambition of leading the curve on innovation in Generic and Brand Drug development and a keen focus on Drug Delivery Systems (DDS).
Historically DrugsTech was part of Center of High Technologies CHEMRAR and its R&D organization – Chemical Diversity Research Institute Ltd. (http://www.chemrar.ru/eng/about/).
In 2010 the company was granted a license for Drug Formulation.
Since 2011 DrugsTech has been avidly developing its own innovative line of Brand Drugs:
• Liposomal Drugs – Transport of cytotoxic and antibacterial drugs
• DDS based on Polymeric Nanoparticles including targeted delivery of drugs across the blood-brain barrier
• Modified release particles – Prolonged-release drug formulations (Depot forms) in micro-sized composition used in neurology, psychiatry.
• Microspheres – Medical supplies for embolization and chemoembolization, covering multiple pharmaceuticals areas such as oncology, urology, and genecology.
In 2010 the company entered into a strategic partnership with one of the largest vertically integrated pharmaceutical holdings in Russia – R-Pharm (http://r-pharm.com/en/).
Under the partnership Drugs Technology started R&D and manufacturing of generic drugs much-needed in Russian Public HealthCare Segment covering more than 1500 Public Hospitals where R-Pharm is a market leader. The partnership allowed R-Pharm to substantially increase its coverage of the market in the Public HealthCare Tender system.
In 2012 R-Pharm acquired a stake in DrugsTech. The deal was completed in 2012 and finalized at the end of 2015.
Today R-Pharm DrugsTech is a pharmaceutical corporation having more than 95 generic drug formulations and 13 innovative dosage forms in more than 12 therapeutic areas. The Portfolio is notable for its Brand drugs with several Drug Candidates in various stages of Clinical Trials.
Standardization of API, Development of finished dosage forms, Preclinical and clinical trials, Scale up and Technology transfer, Launch to the market.